View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsSynairgen 配当と自社株買い配当金 基準チェック /06Synairgen配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Jan 16+ 1 more updateSynairgen plc Announces the Appointment of Martin Murphy to the Board as an Independent Non-Executive Director and Chair of the Remuneration CommitteeSynairgen plc announced the appointment of Martin Murphy to the Board as an independent Non-Executive Director and Chair of the Remuneration Committee, effective immediately. Martin Murphy is a seasoned healthcare veteran with over 25 years of leadership experience in life sciences investment. Previously, Martin Murphy was co-founder of Syncona Limited, a FTSE 250 healthcare investment company, and CEO and Investment Committee Chair of Syncona Investment Management Limited. He now holds various Chair positions and is a Director and founding investor of NASDAQ-listed Autolus Therapeutics plc. Between 2005-2012, he served as a Managing Director of MVM Life Science Partners LLP. Martin holds a PhD from the University of Cambridge and an MA in Biochemistry from the University of Oxford.New Risk • Sep 27New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -UK£6.6m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£6.6m free cash flow). Share price has been highly volatile over the past 3 months (59% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (€8.46m market cap, or US$9.45m). Minor Risk Currently unprofitable and not forecast to become profitable next year (UK£4.5m net loss next year).お知らせ • Sep 18+ 1 more updateSynairgen plc, Annual General Meeting, Oct 10, 2024Synairgen plc, Annual General Meeting, Oct 10, 2024. Location: numis, 9th floor, 45 gresham street, ec2v 7bf, london United KingdomNew Risk • Sep 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (57% average weekly change). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (UK£3.0m net loss in 2 years). Market cap is less than US$100m (€9.66m market cap, or US$10.7m).お知らせ • Sep 05Synairgen plc Announces Stepping Down of Phillip Monk from the Board, Effective December 31, 2024Synairgen plc announced that, following 18 years of service, Dr. Phillip Monk is stepping down from the Board and will leave the Company on December 31, 2024. With Synairgen's resources dedicated to the clinical development of SNG001, Dr. Marcin Mankowski became the Company's Chief Medical Officer in 2023 and will continue to lead the clinical development strategy for SNG001. The Company looks forward to announcing further Board changes ahead of hosting its Annual General Meeting in early October.New Risk • Aug 07New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.53m (US$9.31m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (37% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (€8.53m market cap, or US$9.31m). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (UK£3.0m net loss in 2 years).New Risk • Apr 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings have declined by 37% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€11.5m market cap, or US$12.4m).Board Change • Mar 28Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Non-Executive Director Amanda Radford was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • May 25Synairgen plc, Annual General Meeting, Jun 29, 2023Synairgen plc, Annual General Meeting, Jun 29, 2023, at 09:00 Coordinated Universal Time. Location: Numis, 45 Gresham Street, London EC2V 7BF London United Kingdom決済の安定と成長配当データの取得安定した配当: OMYの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: OMYの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Synairgen 配当利回り対市場OMY 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (OMY)n/a市場下位25% (DE)1.5%市場トップ25% (DE)4.7%業界平均 (Biotechs)2.2%アナリスト予想 (OMY) (最長3年)n/a注目すべき配当: OMYは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: OMYは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: OMYの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: OMYが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YDE 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/07/05 07:34終値2025/04/08 00:00収益2024/06/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Synairgen plc 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関null nullCavendishMark BrewerCavendish
お知らせ • Jan 16+ 1 more updateSynairgen plc Announces the Appointment of Martin Murphy to the Board as an Independent Non-Executive Director and Chair of the Remuneration CommitteeSynairgen plc announced the appointment of Martin Murphy to the Board as an independent Non-Executive Director and Chair of the Remuneration Committee, effective immediately. Martin Murphy is a seasoned healthcare veteran with over 25 years of leadership experience in life sciences investment. Previously, Martin Murphy was co-founder of Syncona Limited, a FTSE 250 healthcare investment company, and CEO and Investment Committee Chair of Syncona Investment Management Limited. He now holds various Chair positions and is a Director and founding investor of NASDAQ-listed Autolus Therapeutics plc. Between 2005-2012, he served as a Managing Director of MVM Life Science Partners LLP. Martin holds a PhD from the University of Cambridge and an MA in Biochemistry from the University of Oxford.
New Risk • Sep 27New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -UK£6.6m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£6.6m free cash flow). Share price has been highly volatile over the past 3 months (59% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (€8.46m market cap, or US$9.45m). Minor Risk Currently unprofitable and not forecast to become profitable next year (UK£4.5m net loss next year).
お知らせ • Sep 18+ 1 more updateSynairgen plc, Annual General Meeting, Oct 10, 2024Synairgen plc, Annual General Meeting, Oct 10, 2024. Location: numis, 9th floor, 45 gresham street, ec2v 7bf, london United Kingdom
New Risk • Sep 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (57% average weekly change). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (UK£3.0m net loss in 2 years). Market cap is less than US$100m (€9.66m market cap, or US$10.7m).
お知らせ • Sep 05Synairgen plc Announces Stepping Down of Phillip Monk from the Board, Effective December 31, 2024Synairgen plc announced that, following 18 years of service, Dr. Phillip Monk is stepping down from the Board and will leave the Company on December 31, 2024. With Synairgen's resources dedicated to the clinical development of SNG001, Dr. Marcin Mankowski became the Company's Chief Medical Officer in 2023 and will continue to lead the clinical development strategy for SNG001. The Company looks forward to announcing further Board changes ahead of hosting its Annual General Meeting in early October.
New Risk • Aug 07New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.53m (US$9.31m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (37% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (€8.53m market cap, or US$9.31m). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (UK£3.0m net loss in 2 years).
New Risk • Apr 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings have declined by 37% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€11.5m market cap, or US$12.4m).
Board Change • Mar 28Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Non-Executive Director Amanda Radford was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • May 25Synairgen plc, Annual General Meeting, Jun 29, 2023Synairgen plc, Annual General Meeting, Jun 29, 2023, at 09:00 Coordinated Universal Time. Location: Numis, 45 Gresham Street, London EC2V 7BF London United Kingdom